Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Rapamycin, a potent immunomodulatory drug, has shown promise in the amelioration of numerous age-associated diseases including cancer, Alzheimer’s disease and cardiac hypertrophy. Yet the elderly, the population most likely to receive therapeutic rapamycin, are already at increased risk for infectious disease; thus concern exists that rapamycin may exacerbate age-associated immune dysfunctions and worsen infection outcomes. Herein, we examined the impact of enteric delivered rapamycin monotherapy (eRapa) on susceptibility of aged (22–24 month) C57BL/6 mice to Streptococcus pneumoniae, the leading bacterial cause of community-acquired pneumonia. Following challenge with S. pneumoniae, administration of eRapa conferred modest protection against mortality. Reduced mortality was the result of diminished lung damage rather than reduced bacterial burden. eRapa had no effect on basal levels of Interleukin (IL)-1α, IL-6, IL-10, IL-12p70, KC, Interferon-γ, Tumor necrosis factor α and Monocyte chemotactic protein-1 in whole lung homogenates or during pneumococcal pneumonia. Previously we have demonstrated that cellular senescence enhances permissiveness for bacterial pneumonia through increased expression of the bacterial ligands Laminin receptor (LR), Platelet-activating factor receptor (PAFr) and Cytokeratin 10 (K10). These proteins are co-opted by S. pneumoniae and other respiratory tract pathogens for host cell attachment during lung infection. UM-HET3 mice on eRapa had reduced lung cellular senescence as determined by levels of the senescence markers p21 and pRB, but not mH2A.1. Mice on eRapa also had marked reductions in PAFr, LR, and K10. We conclude that eRapa protected aged mice against pneumonia through reduced lung cellular senescence, which in turn, lowered bacterial ligand expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 4×
“This is the same dose and drug delivery formulation previously found to be neuroprotective and life extending (Caccamo et al., 2009, 2010; Harrison et al., 2009).”
InfluentialSelf-citationmTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · cited 4×
“…rapamycin's well-established immunomodulatory properties, which include altered T-cell development and dampened antigen presenting cell function (Araki et al., 2009; Battaglia et al., 2005; Hackstein et al., 2003), enthusiasm for the drug's potential as a broad range therapeutic has thus far…”
InfluentialSpilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033 · cited 2×
“In addition to this, rapamycin has shown promise in the amelioration of cognitive deficits in mouse models of Alzheimer's disease (Caccamo et al., 2010; Spilman et al., 2010), reduced the formationof protein inclusions found in numerous neurodegenerative diseases (Caccamo et al.”
Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau
Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881
mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells
Chen, C., Liu, Y., Liu, Y., & Zheng, P. (2009) · Science Signaling · doi:10.1126/scisignal.2000559 · Cited by 680
D’Alessio, F. R., Tsushima, K., Aggarwal, N. R., West, E. E., Willett, M. H., Britos, M. F., Pipeling, M. R., Brower, R. G., Tuder, R. M., McDyer, J. F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36498 · Cited by 564
Johansson, N., Kalin, M., Tiveljung‐Lindell, A., Giske, C. G., & Hedlund, J. (2010) · Clinical Infectious Diseases · doi:10.1086/648678 · Cited by 500 · cited 4×
“pneumoniae (the pneumococcus), a Gram-positive bacterium and the leading bacterial cause of community-acquired pneumonia (Johansson et al., 2010).”
InfluentialRapamycin decelerates cellular senescence
Demidenko, Z. N., Zubova, S. G., Bukreeva, E. I., Pospelov, V. A., Pospelova, T. V., & Blagosklonny, M. V. (2009) · Cell Cycle · doi:10.4161/cc.8.12.8606 · Cited by 391
Orihuela, C. J., Mahdavi, J., Thornton, J., Mann, B., Wooldridge, K. G., Abouseada, N., Oldfield, N. J., Self, T., Ala’Aldeen, D. A. A., & Tuomanen, E. I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36759 · Cited by 303 · cited 1×
“LR serves as a ligand for S. pneumoniae, H. influenzae and Neisseria meningitidis (Orihuela et al., 2009).”
Self-citationCaccamo, A., Majumder, S., Deng, J. J., Bai, Y., Thornton, F. B., & Oddo, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.031278 · Cited by 169
Age‐associated increase in heterochromatic marks in murine and primate tissues
Kreiling, J. A., Tamamori‐Adachi, M., Sexton, A. N., Jeyapalan, J. C., Munoz‐Najar, U., Peterson, A. L., Manivannan, J., Rogers, E. S., Pchelintsev, N. A., Adams, P. D., et al. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2010.00666.x · Cited by 152
Shivshankar, P., Boyd, A. R., Le Saux, C. J., Yeh, I., & Orihuela, C. J. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00720.x · Cited by 117
Self-citation
Cited by
Effect of rapamycin on aging and age-related diseases—past and future
Selvarani, R., Mohammed, S., & Richardson, A. (2021) · GeroScience · doi:10.1007/s11357-020-00274-1 · Cited by 290
Rapamycin Extends Life and Health in C57BL/6 Mice
Zhang, Y., Bokov, A., Gelfond, J., Soto, V., Ikeno, Y., Hubbard, G., Diaz, V., Sloane, L., Maslin, K., Treaster, S., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glt056 · Cited by 279
Self-citationArriola Apelo, S. I., Neuman, J. C., Baar, E. L., Syed, F. A., Cummings, N. E., Brar, H. K., Pumper, C. P., Kimple, M. E., & Lamming, D. W. (2016) · Aging Cell · doi:10.1111/acel.12405 · Cited by 182
“…is still unclear, and rapamycin may not be generally immunosuppressive— indeed, rapamycin treatment improves survival in mouse models of infection (Hinojosa et al., 2012; Hasty et al., 2014) and improves the response to vaccines in both nonhuman primates (Turner et al., 2011) and elderly humans…”
BackgroundInnate immune responses in the ageing lung.
Boe, D. M., Boule, L. A., & Kovacs, E. J. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12881 · Cited by 156
Rapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes
Sataranatarajan, K., Ikeno, Y., Bokov, A., Feliers, D., Yalamanchili, H., Lee, H. J., Mariappan, M. M., Tabatabai-Mir, H., Diaz, V., Prasad, S., et al. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glv170 · Cited by 65
Metadata
- Authors
- Hinojosa, C. A., Mgbemena, V., Van Roekel, S., Austad, S. N., Miller, R. A., Bose, S., & Orihuela, C. J.
- Venue
- Experimental Gerontology
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 47
- Issue
- 12
- Pages
- 958-965
- ISSN
- 0531-5565 (ISSN-L)
- OpenAlex
- W2065091721
- Cited by
- 61
- References
- 12
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.